Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARVINAS, INC.ARVN · Entity 5355 | Chief Scientific Officer | June 17, 2026 | June 18, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARVINAS, INC.
Report date June 17, 2026 · Filed June 18, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 180,390 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Sale · Disposed 2,576 · Balance 180,390 F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on June 17, 2024 pursuant to a durable sale instruction. The sale does not represent a discretionary trade. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on June 17, 2024 pursuant to a durable sale instruction. The sale does not represent a discretionary trade.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 17, 2026 Filed Jun 18, 2026 20:06 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 2,576 | $7.60 | $19,564.72 |
DisclosureSEC source: 0001628280-26-044270 · wk-form4_1781813208.xml · nonDerivative · entry 1 Cacace Angela M · CIK 0002026306 · Chief Scientific Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 180,390 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on June 17, 2024 pursuant to a durable sale instruction. The sale does not represent a discretionary trade. Read SEC document |
| May 11, 2026 Filed May 13, 2026 20:16 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 9,657 | $9.94 | $95,965.47 |
DisclosureSEC source: 0001628280-26-034608 · wk-form4_1778703409.xml · nonDerivative · entry 1 Cacace Angela M · CIK 0002026306 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 182,966 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on May 9, 2025. The sale does not represent a discretionary trade. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 02:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 67,000 | $0.00 Strike: $13.38 | $0.00 |
DisclosureSEC source: 0001628280-26-013535 · wk-form4_1772503231.xml · derivative · entry 2 Cacace Angela M · CIK 0002026306 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 67,000 Underlying: Common Stock · 67,000 shares Expires 2036-02-25 F2 · derivative.exercise_date: The option was granted by the Issuer on February 26, 2026, pursuant to the Plan. The shares underlying the option vest over four years: one-quarter of the shares underlying the award will vest on February 26, 2027, with the remainder of the shares vesting in equal monthly installments following February 26, 2027 through February 26, 2030, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 26, 2026 Filed Mar 3, 2026 02:00 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 45,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-013535 · wk-form4_1772503231.xml · nonDerivative · entry 1 Cacace Angela M · CIK 0002026306 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 192,623 F1 · shares: The restricted stock units (each, an "RSU") were granted by the Issuer on February 26, 2026, pursuant to its 2018 Stock Incentive Plan (the "Plan"), and each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: one-quarter of the RSUs will vest on each of February 26, 2027, February 26, 2028, February 26, 2029 and February 26, 2030, subject to the Reporting Person's continued service with the Issuer on each such vesting date. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 22:09 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 2,571 | $12.16 | $31,263.36 |
DisclosureSEC source: 0001628280-26-011786 · wk-form4_1772057348.xml · nonDerivative · entry 2 Cacace Angela M · CIK 0002026306 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 147,623 F2 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on February 23, 2024. The sale does not represent a discretionary trade. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 22:09 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 1,038 | $12.16 | $12,622.08 |
DisclosureSEC source: 0001628280-26-011786 · wk-form4_1772057348.xml · nonDerivative · entry 1 Cacace Angela M · CIK 0002026306 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,194 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-quarter of the reporting person's restricted stock units (RSUs) granted on February 22, 2023. The sale does not represent a discretionary trade. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 23:13 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 4,592 | $11.89 | $54,598.88 |
DisclosureSEC source: 0001628280-26-009303 · wk-form4_1771456394.xml · nonDerivative · entry 1 Cacace Angela M · CIK 0002026306 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 151,232 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 25% of the reporting person's restricted stock units (RSUs) granted on February 13, 2025. The sale does not represent a discretionary trade. F2 · balance_after: Includes an aggregate of 1,576 shares of common stock of the Issuer previously purchased under and in accordance with the 2018 Employee Stock Purchase Plan of the issuer in transactions exempt under Rule 16b-3. Read SEC document |
| June 17, 2025 Filed Jun 18, 2025 22:04 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 2,583 | $7.49 | $19,346.67 |
DisclosureSEC source: 0001655759-25-000105 · wk-form4_1750284239.xml · nonDerivative · entry 1 Cacace Angela M · CIK 0002026306 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,248 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of 50% of the reporting person's restricted stock units (RSUs) granted on June 17, 2024. Read SEC document |
| May 09, 2025 Filed May 13, 2025 21:16 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 91,000 | $0.00 Strike: $6.61 | $0.00 |
DisclosureSEC source: 0001655759-25-000089 · wk-form4_1747170997.xml · derivative · entry 2 Cacace Angela M · CIK 0002026306 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 91,000 Underlying: Common Stock · 91,000 shares Expires 2035-05-08 F2 · derivative.exercise_date: The option was granted by the Issuer on May 9, 2025, pursuant to the Plan. The shares underlying the option will vest over two years: 1/2 of the shares underlying the award shall vest on May 9, 2026, with the remainder of the shares vesting on May 9, 2027, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| May 09, 2025 Filed May 13, 2025 21:16 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 59,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001655759-25-000089 · wk-form4_1747170997.xml · nonDerivative · entry 1 Cacace Angela M · CIK 0002026306 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 156,831 F1 · shares: The restricted stock units (each, an "RSU") were granted by the issuer on May 9, 2025, pursuant to its 2018 Stock Incentive Plan (the "Plan") and each RSU represents a contingent right to receive one share of the issuer's common stock upon settlement for no consideration. The RSUs will vest over two years: 1/2 of the shares underlying the award shall vest on May 9, 2026, with the remainder of the shares vesting on May 9, 2027, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 24, 2025 Filed Feb 25, 2025 11:35 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 1,146 | $16.55 | $18,966.30 |
DisclosureSEC source: 0001655759-25-000052 · wk-form4_1740483329.xml · nonDerivative · entry 2 Cacace Angela M · CIK 0002026306 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 97,231 F3 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-quarter of the reporting person's RSUs granted on February 22, 2023. Read SEC document |
| February 24, 2025 Filed Feb 25, 2025 11:35 UTC | ARVINAS, INC. ARVN · Entity 5355 | SaleCommon Stock | 3,061 | $16.75 | $51,271.75 |
DisclosureSEC source: 0001655759-25-000052 · wk-form4_1740483329.xml · nonDerivative · entry 1 Cacace Angela M · CIK 0002026306 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 98,377 F1 · shares: This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-half of the reporting person's restricted stock units (RSUs) granted on February 23, 2024. F2 · balance_after: Includes an aggregate of 494 shares of the issuer's common stock purchased under and in accordance with the issuer's 2018 Employee Stock Purchaser Plan in transactions exempt under Rule 16b-3. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 00:57 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 74,960 | $0.00 Strike: $17.67 | $0.00 |
DisclosureSEC source: 0001655759-25-000021 · wk-form4_1739926615.xml · derivative · entry 2 Cacace Angela M · CIK 0002026306 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 74,960 Underlying: Common Stock · 74,960 shares Expires 2035-02-12 F2 · derivative.exercise_date: The option was granted by the Issuer on February 13, 2025, pursuant to the Plan. The shares underlying the option vest over four years: 1/4 of the shares underlying the award will vest on February 13, 2026, with the remainder of the shares vesting in equal monthly installments following February 13, 2026 through February 13, 2029, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| February 13, 2025 Filed Feb 19, 2025 00:57 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 49,092 | $0.00 | $0.00 |
DisclosureSEC source: 0001655759-25-000021 · wk-form4_1739926615.xml · nonDerivative · entry 1 Cacace Angela M · CIK 0002026306 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,944 F1 · shares: The restricted stock units (each, an "RSU") were granted by the issuer on February 13, 2025, pursuant to its 2018 Stock Incentive Plan (the "Plan") and each RSU represents a contingent right to receive one share of the issuer's common stock upon settlement for no consideration. The RSUs will vest over four years: 25% of the RSUs will vest on each of February 13, 2026, February 13, 2027, February 13, 2028 and February 13, 2029, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| June 17, 2024 Filed Jun 18, 2024 21:53 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantStock Option (right to buy) · Derivative | 24,632 | $0.00 Strike: $24.94 | $0.00 |
DisclosureSEC source: 0001655759-24-000098 · wk-form4_1718747603.xml · derivative · entry 2 Cacace Angela M · CIK 0002026306 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,632 Underlying: Common Stock · 24,632 shares Expires 2034-06-16 F2 · derivative.exercise_date: The option was granted by the Issuer on June 17, 2024, pursuant to the Plan. The shares underlying the option will vest over two years: 1/2 of the shares underlying the award shall vest on June 17, 2025, with the remainder of the shares vesting on June 17, 2026. Read SEC document |
| June 17, 2024 Filed Jun 18, 2024 21:53 UTC | ARVINAS, INC. ARVN · Entity 5355 | GrantCommon Stock | 15,995 | $0.00 | $0.00 |
DisclosureSEC source: 0001655759-24-000098 · wk-form4_1718747603.xml · nonDerivative · entry 1 Cacace Angela M · CIK 0002026306 · Chief Scientific Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 51,852 F1 · shares: The restricted stock units (each, an "RSU") were granted by the issuer on June 17, 2024, pursuant to its 2018 Stock Incentive Plan (the "Plan") and each RSU represents a contingent right to receive one share of the issuer's common stock upon settlement for no consideration. The RSUs will vest over two years: 1/2 of the shares underlying the award shall vest on June 17, 2025, with the remainder of the shares vesting on June 17, 2026. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.